TFF Pharmaceuticals, Inc. (TFFP)
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of TFF Pharmaceuticals, Inc. ("TFF" or the "Company") (NASDAQ:TFFP). Investors who purchased TFF Pharmaceuticals, Inc. securities are encouraged to obtain additional information and assist the investigation.
The investigation concerns whether TFF and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
On November 1, 2022, TFF issued a press release "announc[ing] program updates for Voriconazole Inhaled Powder (TFF VORI) and Tacrolimus Inhaled Powder (TFF TAC) clinical programs." TFF stated that "[w]e expect to deliver preliminary patient data from the Phase 2 study of TFF VORI in the first quarter of 2023 and TFF TAC in the second quarter of 2023," explaining that "[t]he timing of data release has been updated due to several challenges related to staffing shortages, shipping, and global supply chain delays." On this news, TFF's stock price fell sharply in after-market trading.
If you are aware of any facts relating to this investigation or purchased TFF Pharmaceuticals, Inc. shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.